



# PROGRAMME

(SUBJECT TO ALTERATION)

**Monday 17th October**

## FLEMING ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.20 **WELCOME ADDRESS** Rob Pollock & London Organising Committee

### ADULT LIMB SALVAGE SURGERY - LOWER LIMB

**Chairs: Prof Philipp Funovics / Prof Panayiotis Papagelopoulos**

08.40	143	Trabecular metal collars in Endoprosthetic Replacements: do they osteointegrate? <i>Dr Ewen Fraser, Glasgow Royal Infirmary, Glasgow, United Kingdom</i>
08.45	324	Early Radiological Outcomes of a Fully Porous Bridging Collar in Lower Limb Endoprosthetic Reconstructions: A Case Matched Study. <i>Mr M A Siddiqi, Nuffield Orthopaedic Center, Oxford, United Kingdom</i>
08.50	58	Proximal Tibia Reconstructions after Oncological Resection. <i>Dr Federico Sacchetti, Orthopedic Oncology and Complex Reconstruction Unit, Florence, Italy</i>
08.55	276	Oncologic and functional outcomes after excision of proximal femur primary bone tumours and hemiarthroplasty. <i>Dr Rohit, Tata Memorial Hospital, Mumbai, India</i>
09.00		Questions

- 09.15 107 Does vascularized on-lay fibula graft provide additional benefit in the biological reconstruction of large segment intercalary femur defects? *Dr Suraj Hindiskere, HCG Hospital, Bangalore, India*
- 09.20 54 Functional quadriceps reconstruction by means of a neurotized gracilis transfer and spare parts management. *Dr Javier Buendia, Hospital Clínico San Carlos, Madrid, Spain*
- 09.25 45 Does the osteosynthesis affect the complication rate in intercalary femur allograft reconstructions. *Dr Jose Albergo, Hospital Italiano de Buenos Aires, Buenos Aires, Argentina*
- 09.30 275 Early outcomes of Allograft/Autograft prosthesis composite for reconstruction in lower limb tumors. A single institution study. *Prof Ashish Gulia, Tata Memorial Hospital, Mumbai, India*
- 09.35 328 Distal femur pedicle frozen autograft reconstruction for malignant bone tumors. *Dr Juan P. Zumarraga, Universidad San Francisco de Quito, Quito, Ecuador*
- 09.40 265 Biological reconstruction with distraction osteogenesis following resection of bone sarcomas: *Dr Anthony Bozzo, A prospective study. MSKCC, NYC, USA*
- 09.45 Questions

09.55 **DEBATE 1: EPR or Biology for lower limb reconstruction?**  
**Moderators: Prof Philipp Funovics / Prof Panayiotis Papagelopoulos**  
 I Heal with Steel – endoprostheses are the best option reconstruction of the lower extremities. *Mr Duncan Whitwell, Oxford Sarcoma Service, UK*  
 Where biological reconstruction wins. *Prof Ashish Gulia, Tata Memorial Hospital, Mumbai, India*

10.15 **REFRESHMENTS**

**ADULT LIMB SALVAGE SURGERY - UPPER LIMB**

**Chairs: Prof Pietro Ruggieri / Prof Thomas Baad-Hansen**

- 10.45 63 Complex shoulder extra-articular resection and reconstruction – a novel design. *Dr Jan Lesensky, Charles University, Prague, Czech Republic*
- 10.50 170 Outcomes of Oncologic Scapular Resection and Reconstruction. *Dr Matthew Houdek, Mayo Clinic, Rochester, MN, USA*
- 10.55 29 Anatomical and reverse megaprosthesis in proximal humerus reconstructions after oncologic resections: a systematic review and meta-analysis. *Dr Andrea Sambri, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy*
- 11.00 198 Custom 3D implants for glenoid tumor reconstruction should be designed as reverse total shoulder arthroplasty. *Prof Thomas Schubert, Cliniques universitaires Saint-Luc, Department of Orthopaedic Surgery, Brussels, Belgium*
- 11.05 Questions

- 11.15 88 Reconstruction of Proximal Humerus Resections With Mesh Cone-Nail-Cement Spacer Construct. *Dr Anto Gopurathingal, HCG Hospital, Bangalore, India*
- 11.20 235 Prosthetic reconstruction of the shoulder after resection of proximal humerus bone tumors. *Mr Ioannis Trikoupis, National and Kapodistrian University of Athens, Athens, Greece*
- 11.25 40 Intercalary reconstruction with Vascularized Fibula after resection for Primary Bone Tumors of the Humerus. *Dr Roberto Scanferla, Orthopaedic Oncology Unit, AOU Careggi, Florence, Italy*
- 11.30 171 Durability of Intercalary Endoprosthesis for Humeral Reconstruction. *Dr Joshua Labott, Mayo Clinic, Rochester, MN, USA*
- 11.35 118 Prosthoprosthesis composite Limb salvage for massive Chondrosarcoma of the proximal humerus- maiden use of 3D printing to reconstruct multiple bones around the shoulder: a video demonstration. *Dr Pramod Chinder, HCG Hospital, Bangalore, India*
- 11.40 Questions

11.50

### DEBATE 2: EPR or Biology for proximal humeral tumours?

**Moderators: Chairs: Prof Pietro Ruggieri / Prof Thomas Baad-Hansen**

Endoprosthetic reconstruction of the shoulder after oncology resection is the future. *TBC*

Big metal implants don't work in the shoulder – expensive and over rated. *Dr Marco Manfrini, Rizzoli*

12.15

### INVITED LECTURE

Orthopaedics and oncology at war in Ukraine: bone defect management

*Dr Oleg Vyrva, Chief Medical Officer, Sytenko Institute of Spine and Joint Pathology, Ukraine*

12.30

### LUNCH

**STRYKER SYMPOSIUM: EU-MDR & UK Regulation and Advocacy UPDATE. *Michel Marboeuf, RA Senior Director, Stryker Corporate. Vice Chair of the Regulatory Affairs Committee MedTech Europe. Chair of European working group Advamed***

### LIMB SALVAGE SURGERY IN CHILDREN - BIOLOGICAL RECONSTRUCTION

**Chairs: Dr Marco Manfrini / Mr Alex Woollard**

- 13.30 186 Autobiologic reconstruction of the hip with dual vascularized fibula grafts in the immature skeleton. A 20-year follow-up with functional evaluation. *Prof Peter Bergh, Dept of Orthopedics, Gothenburg, Sweden*
- 13.35 187 Autobiologic reconstruction of the knee with dual vascularized fibula grafts in the immature skeleton. A 20-year follow-up with functional evaluation. *Dr Christina Berger, Dept of Orthopedics, Gothenburg, Sweden*
- 13.40 188 Autobiologic reconstruction of the shoulder with a single vascularized fibula graft in the immature skeleton. A 20-year follow-up with functional evaluation. *Prof Örjan Berlin, Dept of Orthopedics, Gothenburg, Sweden*
- 13.45 127 Vascularised fibula physis transfer for upper limb paediatric sarcoma defects. *Mr Harsh Samarendra, Royal Free NHS Foundation Trust, London, United Kingdom*
- 13.50 Questions

- 14.00 128 Pedicled ipsilateral Fibula with Allograft for reconstruction of Paediatric Tibial Defects. *Mr Paul Caine, Royal Free NHS Foundation Trust, London, United Kingdom*
- 14.05 266 Reliability of composite xeno-hybrid bone grafts in pediatric orthopaedic oncology. *Dr Michele Boffano, Orthopaedic Oncology AOU Citta' della Salute e della Scienza, Torino, Italy*
- 14.10 121 Joint-retaining resections for pediatric lower limb sarcomas with intercalary allograft & vascularised fibula reconstructions. *Mr Bart Kowalczyk, Pediatric Musculoskeletal Oncology Center, University Children's Hospital, Krakow, Poland*
- 14.15 104 Have those tumours not crossing the physis a different outcome? A Reassessment of the Barrier Effect of the Physis against Metaphyseal Osteosarcoma. *Dr José María Lamo-Espinosa, Clínica Universidad de Navarra, Pamplona, Spain*
- 14.20 Questions

### LIMB SALVAGE SURGERY IN CHILDREN - EPR

**Chairs: Dr Eric Mascalcard / Mr Sam Patton**

- 14.30 293 Mid-term results of modular noninvasive expandable endoprosthesis after bone tumor resection in skeletal immature patients. *Dr Ioannis Trikoupis, First Department of Orthopedic Surgery, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece*
- 14.35 20 Multiplanar tibia deformities and growth disturbance in patients with expandable distal femur replacement. *Dr Ahmad Shehadeh, KHCC, Amman, Jordan*
- 14.40 52 Tumor endoprosthetic defect reconstruction with customized implants in children and younger adolescents. *Ms Nina Myline Engel, University hospital Essen, Essen, Germany*
- 14.45 25 3 epochs in the use of Implantcast growing endoprosthesis - Experience of the Polish Group for the treatment of primary malignant bone tumors. *Dr Andrzej Szafranski, The Children's Memorial Health Institute, Warsaw, Poland*
- 14.50 Questions
- 15.00 113 A comparison of oncological, surgical, and functional outcomes in endoprosthetic reconstruction versus rotationplasty for paediatric lower extremity bone sarcoma. *Mr Jonathan Perera, Royal National Orthopaedic Hospital, Stanmore, United Kingdom*
- 15.05 24 The experience of the Polish Group for the treatment of primary malignant bone tumors in children and adolescents in reconstructions with the use of growing endoprostheses. *Dr Andrzej Szafranski, The Children's Memorial Health Institute, Warsaw, Poland*
- 15.10 277 Proximal femur replacement after excision of primary bone tumors in children – do they behave different compared to adults? *Prof Ashish Gulia, Tata Memorial Hospital, Mumbai, India*
- 15.15 194 Hip Reconstruction for Proximal Femur Sarcomas in the first decade of life. *Dr Marco Manfrini, Istituto Ortopedico Rizzoli, Bologna, Italy*
- 15.20 Questions

## 15.30 REFRESHMENTS

### KEYNOTE LECTURE

- 16.00 288 Forty-year experience with primary bone sarcoma local control surgery: A retrospective review of limb salvage, rotationplasty and amputation outcomes.  
*Dr Mark Gebhardt, Boston Children's Hospital, Boston, USA*

### BIOLOGICAL RECONSTRUCTION

**Chairs: Dr Nicola Fabbri / Dr Luke Johnson**

- 16.15 83 A Single Institution Experience Of Bone Allograft In Musculoskeletal Oncology - A Review Of 135 Cases. *Dr Amar Kamat, HCG Hospital, Bangalore, India*
- 16.20 263 Mid to long-term clinical outcome of tumor-devitalized autografts in limb-sparing surgery for bone and soft tissue tumors - A nationwide multicenter study. *Dr Akihiko Takeuchi, Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan*
- 16.25 315 Complications of Liquid Nitrogen Recycled Bones: The dark side of the moon! *Dr Osman Emre Aycan, Baltalimani Bone Diseases Training and Research Hospital, Istanbul, Turkey*
- 16.30 292 Proximal fibula resection for tumors - case series and technical note. *Dr Marisa Valentini, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*
- 16.35 246 Is there any difference in mid to long term results of LCL reconstructions after proximal fibula resections? *Dr Osman Emre Aycan, Baltalimani Bone Disease Training and Education Hospital, Istanbul, Turkey*
- 16.40 Questions

### NOVEL LIMB SALVAGE TECHNIQUES

**Chairs: Dr Mark Gerhardt / Dr Minna Laitinen**

- 16.50 21 The outcome of joint sparing endoprosthesis (JSE), as a reconstructive modality for juxta-articular bone tumors. *Dr Ahmad Shehadeh, KHCC, Amman, Jordan*
- 16.55 112 Knee joint sparing surgery for primary bone sarcoma resections with the use of 3D printed patient-specific instruments. *Dr Amit Benady, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel*
- 17.00 340 Joint sparing endoprostheses of the long bones in the treatment of musculo-skeletal tumours. *Mr Craig Gerrand, Royal National Orthopaedic Hospital, Stanmore, UK*

17.05	124	Novel Patient-Specific Additive-Manufactured Lattice Titanium Implants for Critical-Sized Bone Reconstruction. <i>Dr Amit Benady, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel</i>
17.10	68	Different techniques for unicondylar reconstruction around knee: comparative study between osteoarticular bone grafts VS custom-made prostheses. <i>Dr Benedetta Spazzoli, Istituto Ortopedico Rizzoli, Bologna, Italy</i>
17.15	30	Comparison of different reconstruction techniques after distal tibial resection for primary bone cancer. <i>Dr Andrea Sambri, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy</i>
17.20		Questions
17.30		<b>EMSOS Lecture - Introduced by Mr Craig Gerrand and Mr Jonathan Perera</b> Improving precision in sarcoma management <i>Prof Jay Wunder, Mount Sinai Hospital, Toronto, Canada</i>
18.00		<b>EMSOS General Assembly</b> <b>Welcome Reception</b>

## Monday 17th October

### WHITTLE ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome & Housekeeping**

#### SESSION 1: LOCALLY AGGRESSIVE MESENCHYMAL TUMOURS (TGCT/FIBROMATOSIS)

Chairs: **Dr Vasilios Karavasilis (Medical Oncologist, UCLH, London) / Prof. Michael Van De Sande (Surgeon, LUMC, Leiden)**

08.40 **KEYNOTE LECTURES**

The Role of Surgery for TGCT. *Ms Heledd Havard, Consultant Surgeon, The Royal National Orthopaedic Hospital Hospital*

Non-surgical management of TGCT. *Dr Beatrice Seddon, Consultant Clinical Oncologist UCLH*

A Patient Physician Collaborative Effort for a Better TGCT Experience. *Sydney Stern*

Pathology of locally aggressive mesenchymal tumours (TGCT and fibromatosis). *Dr Roberto Tirabosco, Consultant Pathologist, RNOH*

Non-surgical management of Fibromatosis. *Dr Palma Dileo, Consultant Medical Oncologist, ULCH*

Radiotherapy for Fibromatosis. *Dr Franel Le Grange, Consultant Clinical Oncologist, UCLH*

**ONCOLOGY FLASH SESSION - RADIOTHERAPY**

**Chairs: Dr Franel Le Grange (Radiation Oncologist, UCLH, London), Dr Siddhartha Laskar (Radiation Oncologist, Tata Memorial , Mumbai)**

- 10.40 251 Radiotherapy in Hip Heterotopic ossification: 3 cases reports. *Dr Diana Correia, Centro Hospitalar e Universitário de Coimbra, Coimbra, Portugal*
- 10.45 109 Outcomes of Brachytherapy in soft tissue sarcoma of the extremities: Tips to burn the tumour and not our fingers with experience of 58 cases from a single institute. *Dr Pramod Chinder, HCG Hospital, Bangalore, India*
- 10.50 163 Wound complications in soft tissue sarcoma treated with Preoperative Radiotherapy. *Mr Duncan Whitwell, Oxford Sarcoma Service, UK*
- 10.55 178 The role of post-operative radiotherapy in osteosarcoma: a retrospective analysis from the London Sarcoma Service (LSS) *Dr Asad Mahmood, UCLH, London, United Kingdom*
- 11.00 213 Interstitial brachytherapy for organ and function preservation in soft tissue sarcomas: Long term outcomes. *Prof Siddhartha Laskar, Tata Memorial Hospital, Homi Bhabha National Institute, Mumbai, India*
- 11.05 335 How does bone strength change after radiation therapy for metastatic disease, can we avert pathologic fractures. CT base biomechanical finite element analysis of patients with bone metastases to the femur. *Dr Amir Sternheim, Department of Orthopaedic Oncology, Tel-Aviv Medical Center, Tel-Aviv, Israel*
- 11.10 Questions

**ONCOLOGY FLASH SESSION - GENERAL**

**Chairs: Dr Rachel Windsor (Paeds Oncology, UCLH, London), Dr Emanuela Palmerini (Medical Oncologist, Bologna, Italy)**

- 11.20 175 Safety and efficacy of vimseltinib in tenosynovial giant cell tumour (TGCT): Long-term phase 1 update. *Dr Michiel van de Sande, Leiden University Medical Center, Leiden, Netherlands*
- 11.25 176 Efficacy and safety of vimseltinib in tenosynovial giant cell tumour (TGCT): Phase 2 expansion. *Dr Michiel van de Sande, Leiden University Medical Center, Leiden, Netherlands*
- 11.30 193 Living with sarcoma in childhood: An in-depth qualitative analysis of psychosocial factors. *Rachel Taylor, University College London Hospitals NHS Foundation Trust, London, United Kingdom*
- 11.35 185 Improving survival of children with osteosarcoma: an international cooperation approach. *Dr Valentina Di Martino, Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy*
- 11.40 Questions

- 11.50 15 Predictors of survival ,local recurrence and metastasis in Leiomyosarcoma of trunk wall and extremities: A multicentre data analysis of 488 patients. *Mr Sudhir Kannan, Newcastle University, Newcastle Upon Tyne, United Kingdom*
- 11.55 214 Drug combination screening as a translational approach toward an improved drug therapy for chordoma. *Dr Susanne Scheipl, Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria*
- 12.00 183 Factors influencing the outcome of patients suffering from primary sacral Ewing Sarcoma. *Prof Jendrik Harges, University Hospital Essen, Essen, Germany*
- 12.05 332 Integration of Transcriptome and Metabolome to identify novel biomarkers for soft tissue sarcoma. *Dr Serena Pillozzi, Department of Experimental and Clinical Medicine, University of Florence, Florence, Italy*
- 12.10 145 Follow-up after curative surgical treatment of soft-tissue sarcomas: patients receiving more or less visits than protocol and association with recurrence. *Mrs Anouk Kruiswijk, Leiden University Medical Center, Leiden, Netherlands*
- 12.15 139 Is bone marrow aspiration and biopsy necessary in the initial staging of extraskeletal Ewing sarcoma. *Dr Samuel Broida, Mayo Clinic, Rochester, MN, USA*
- 12.20 Questions

12.30 **LUNCH**

## **SESSION 2: ULTRA-RARE SARCOMA**

**Chairs: Dr Hans Merks (Paed Oncologist, Princess Maxima Centrum, Utrecht) / Dr Beatrice Seddon (Radiation Oncologist, UCLH, London)**

### **KEYNOTE LECTURES**

- 13.30 Ultra-Rare Sarcoma. *Professor Silvia Stacchiotti, Consultant Medical Oncologist, Fondazione IRCCS Istituto Nazionale Tumori, Milan*  
 Round Cell Tumours. *Dr Sandra Strauss, Consultant Medical Oncologist, UCLH*  
 Epithelioid Hemangioendothelioma. *Prof Robin Jones, Consultant Medical Oncologist, The Royal Marsden Hospital*  
 Clear Cell Sarcoma. *Dr Nishalan Pillay, Consultant Pathologist, RNOH and UCL*  
 Alveolar Soft Part Sarcoma. *Nadia Hindi, Medical Oncologist, Oncology Department, Fundación Jimenez Diaz University Hospital, Madrid*

15.30 **REFRESHMENTS**

## **ONCOLOGY FLASH SESSION - ONCOLOGY BONE TUMOURS**

**Chairs: Dr Sandra Strauss (Medical Oncology, UCLH, London) / Dr Maria Michelagnoli (Paeds Oncology, UCLH, London)**



- 16.00 69 What is the impact of treatment delays on the outcome of patient with high-grade osteosarcoma? A retrospective analysis of data from the EURAMOS-1 trial. *Dr Dimosthenis Andreou, Medical University of Graz, Graz, Austria*
- 16.05 282 Osteosarcoma in Ukraine. *Prof Oleg Vyrva, Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine*
- 16.10 321 FOSTER (Fight Osteosarcoma Through European Research): an European Osteosarcoma Consortium for research and cure for osteosarcoma patients. *Dr Emanuela Palmerini, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*
- 16.15 144 Two rare sides of one rare disease: ewing sarcoma with and as secondary malignancies – epidemiological and clinical analysis of an international trial registry. *Dr Stefan K. Zöllner, University Hospital Essen, Pediatrics III, Essen, Germany*
- 16.20 Questions
- 16.30 180 A propensity-score weighted analysis of local treatment modalities for Ewing Sarcoma - Report from the Ewing 2008 trial. *Philip Heesen, University of Duisburg Essen, Essen, Germany*
- 16.35 230 Clinical efficacy and toxicity profiles of neoadjuvant chemotherapy in the treatment of non-metastatic Ewing's sarcoma: ISG/SSGIII and Euro-E.W.I.N.G. 99 compared. *Dr Virginia Santarini, University Hospital Essen, Pediatrics III, West German Cancer Centre, Essen, Germany*
- 16.40 125 Treatment Outcomes of Extraskkeletal Ewing Sarcoma: Should Radiotherapy Be Combined with Chemotherapy and Surgery in All Patients? *Dr Matthew Houdek, Mayo Clinic, Rochester, MN, USA*
- 16.45 261 Proton Beam Therapy for Ewing sarcoma in Children and Young Adults: Clinical Results from the Prospective Registries KiProReg and ProReg. *Prof Beate Timmermann, Department of Particle Therapy, University Hospital Essen, West German Proton Therapy Centre Essen (WPE), Essen, Germany*
- 16.50 Questions

#### ONCOLOGY FLASH SESSIONS - SYSTEMIC ANTI-CANCER THERAPY IN SOFT TISSUE SARCOMA

- 17.00 13 Neoadjuvant chemotherapy and endoprosthetic reconstruction for lower extremity sarcomas: does timing impact complication rates? *Dr Aaron Gazendam, McMaster Hospital, Hamilton, Canada*
- 17.05 108 Pazopanib in advanced bone and soft tissue tumours: Is it worth it when there is nothing else to offer? *Dr Suraj Hindiskere, HCG Hospital, Bangalore, India*
- 17.10 42 Post-treatment tumor necrosis in soft tissue sarcoma following neoadjuvant therapy – what is the role of chemo- and radiotherapy? What does it mean for the prognosis? *Prof Hans Roland Dürr, Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 17.15 308 Impact of DNA-damage repair dysregulation on chemotherapy response in novel soft tissue sarcoma models. *Mr Nils Dieckmann, University Hospital Essen, Medical Oncology, Essen, Germany*
- 17.20 290 Characteristics and therapy of CIC-sarcoma - a comparison to classical Ewing sarcoma. *Mr Daniel A. F. Bernard, University Hospital Essen, Essen, Germany*

- 17.25 309 Is there a role for adjuvant chemotherapy for patients with primary, high-grade, non-metastatic myxofibrosarcoma? *Dr Emanuela Palmerini, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*
- 17.30 Questions
- 17.40 **Close of Session**

## Monday 17th October

### GIELGUD ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome & Housekeeping**

#### SESSION 1: INNOVATIVE WAYS OF WORKING

**Chairs: Julie Woodford, Macmillan Nurse Consultant. Sarcoma Clinical Director & Clinical Lead, London Sarcoma Service**  
**Shea Byrne, Orthopaedic Oncology Therapies Clinical Lead, RNOH, Stanmore**

#### INVITED LECTURES

- 08.35 Innovations in TYA care. *Dr Louise Soanes Chief Nurse Teenage Cancer Trust*
- 09.00 Never let a crisis go to waste - building for the future. *Dr Natalie Doyle, Nurse Director-Patient Experience, The Royal Marsden NHS Founda*

#### FREE PAPERS - SESSION 1

- 09.20 311 Sarcoma UK Support Line. *Sam Hackett / Carly McDonald, Sarcoma UK, London, United Kingdom*
- 09.28 157 Assessing the impact of a physiotherapy follow-up clinic in paediatric sarcoma rehabilitation. *Rebecca Pickford, Royal National Orthopaedic Hospital, London, United Kingdom*
- 09.36 341 The Role of the Specialist Sarcoma Radiographer. *Ms Clare David, University College Hospital, London, United Kingdom*
- 09.44 241 Advantages of the Band 6 Sarcoma Clinical Nurse Specialist Development Role within the London Sarcoma Service. *Mrs Lucy Bridgeman, The Royal National Orthopaedic Hospital, Stanmore, London, United Kingdom*
- 09.52 135 Embedding Advanced Care Practitioners (ACP's) in sarcoma follow up. *Mrs Abigail McCarthy, Royal National Orthopaedic Hospital, London, United Kingdom*
- 10.00 Questions

## 10.15 REFRESHMENTS

### SESSION 2: PHYSICAL ACTIVITY - WHERE ARE WE NOW?

**Chairs: Suzy Hudson, Macmillan Personalised Cancer Care Lead, RNOH Stanmore  
Abby McCarthy, Macmillan Highly Specialist Physiotherapist, RNOH Stanmore**

#### INVITED LECTURES

- 10.45 SafeFit through the microscope. *June Davis, Allied Health Professional Advisor, MacMillan Cancer Support*  
11.05 Supporting and inspiring people to Move Against Cancer. *Helen Murrey, MOVE Cancer Rehabilitation Specialist*

#### FREE PAPERS - SESSION 2

- 11.25 200 Assessment of physical activity in children and adolescents after malignant bone tumour surgery. *Dr W. Peter Bekkering, Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands*  
11.30 155 #JOGLE - A service evaluation. Does a group exercise challenge increase physical activity levels in teenagers and young adults? *Rebecca Pickford, Royal National Orthopaedic Hospital, London, United Kingdom*  
11.35 322 Improving Physiotherapy Services for Sarcoma Patients Across the East of England Cancer Alliance: Creation of the 'STAR Class' - Sarcoma Telehealth Activity & Rehabilitation Education Class. *Mrs Nicola Day, Cambridge University Hospitals NHS Trust, Cambridge, United Kingdom*  
11.40 16 Return to Sports Following Lower Limb Musculoskeletal Tumour Surgery - A Systematic Review. *Mr Metin Tolga Buldu, RNOH, Stanmore, United Kingdom*  
11.45 Questions

#### INVITED LECTURES

- 11.55 MDT approach to bone metastases. *Ms Kate Spacey, RNOH*  
12.15 Staying Active with Bone Metastases - Latest Guidelines and Research Updates. *Dr Emer Guinan, Assistant Professor in Interprofessional Learning, Trinity College, Dublin*

## 12.35 LUNCH

### SESSION 3: PSYCHOSOCIAL IMPACT OF A SARCOMA DIAGNOSIS

**Chairs: Dr Rachel Taylor, Director of the Centre for Nurse Midwife and AHP Research  
Roger Wilson CBE, Patient Representative**

#### INVITED LECTURE

- 13.30 The Patient Voice - Mapping Today - Building Tomorrow. *Roger Wilson CBE*

### FREE PAPERS - SESSION 3

- 13.50 211 Development of a patient-reported outcome measure specific to sarcoma: the Sarcoma Assessment Measure (SAM). *Dr Rachel Taylor, University College London Hospitals NHS Foundation Trust, London, United Kingdom*
- 14.00 79 Health-Related Quality of Life of bone and soft-tissue tumor patients around the time of diagnosis. *Ms Anouk Kruiswijk, Leiden University Medical Center, Leiden, Netherlands*
- 14.10 136 Concerns Raised During Holistic Needs Assessment by Patients Following Sarcoma Diagnosis and Treatment. *Mrs Suzy Hudson, Royal National Orthopaedic Hospital, London, United Kingdom*
- 14.20 301 What are the barriers to mental health care for patients with sarcoma? *Prof John Healey*

### INVITED LECTURES

- 14.30 Sarcoma, a patients journey. *Nina Squire, Expert patient*
- 14.50 Fear of Recurrence: what, when, who and why? *Dr Lesley Storey, Senior lecturer in Psychology, Anglia Ruskin University*

### 15.10 REFRESHMENTS

### SESSION 4: FLASH SESSION: RECENT ADVANCES IN THE FIELD OF FUNCTIONAL OUTCOMES IN MUSCULOSKELETAL ONCOLOGY

**Chairs: Dr Sherron Furtado, Senior Sarcoma Research Physiotherapist and Lead on the Musculoskeletal Cancer Rehabilitation Programme, Royal National Orthopaedic Hospital NHS Trust (RNOH), London, Stanmore**

**Dr. W. Peter Bekkering, Pediatric Physical therapist and Postdoc Researcher, Princess Máxima Center of Pediatric Oncology, Utrecht, The Netherlands.**

### 15.30 INVITED TALKS - EAST vs WEST

Paediatric physiotherapeutic care and research for children with malignant bone tumours in the Princess Maxima Center for Paediatric Oncology. *Dr. W. Peter Bekkering. Pediatric Physical therapist and Postdoc Researcher. Princess Máxima Center of Pediatric Oncology, Utrecht, The Netherlands.*

Physiotherapy Management of Bone and soft tissue Tumors in a Tertiary Cancer hospital in India.  
*Dr Anuradha Daptardar, Officer In-charge of Physiotherapy Department, Tata memorial cancer center, Mumbai, India.*

Functional Outcomes and Rehabilitation after Sarcoma Surgery - Emerging Technologies, Innovative Therapies and Future Vision of the London Sarcoma Service. *Dr Sherron Furtado, London UK. Senior Sarcoma Research Physiotherapist and Lead on the Musculoskeletal Cancer Rehabilitation Programme, RNOH, Stanmore*

#### **FREE PAPERS - SESSION 4**

- 16.00 8 Defining minimally important differences in functional outcomes for musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction. *Dr Aaron Gazendam, McMaster University, Hamilton, Canada*
- 16.05 9 Predictors of functional recovery among musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction. *Dr Aaron Gazendam, McMaster University, Hamilton, Canada*
- 16.10 329 The Sarcoma-Specific Quality of Life Study (SARC-QoL): identifying key domains of health-related quality of life in adult patients with extremity soft tissue sarcoma. *Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA*
- 16.15 300 Expectations of mobility following lower limb massive endo-prosthetic replacement (EPR) for primary bone sarcoma in children. *Dr Sherron Furtado, Royal National Orthopaedic Hospital NHS Trust, London, United Kingdom*
- 16.20 Discussion & Q/A session
- 16.40 Break

#### **INTERACTIVE SESSION**

- 17.00 20 Years of Speaking Cancer. *Brian Lobel, Professor of Theatre & Performance, Rose Bruford College, UK*
- 17.45 **Close of Session**



# PROGRAMME

(SUBJECT TO ALTERATION)

**Tuesday 18th October**

## FLEMING ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 [Welcome / Housekeeping](#)

### SOFT TISSUE SARCOMA

**Chairs: Dr Michele Boffano / Prof Andreas Leithner**

08.35	216	Elbow synovial sarcoma - biopsy and imaging challenges in recurrent disease - case presentation. <i>Dr Mihai Nica, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania</i>
08.40	19	Synovial sarcoma: A clinicopathological study. <i>Dr Mustafa Karaca, Ankara University Medical Faculty, Ankara, Turkey</i>
08.45	302	Myxoinflammatory fibroblastic sarcoma: a case series from two sarcoma centre. <i>Dr Marco Focaccia, Orthopedic Oncology Division, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy</i>
08.50	77	What treatment modality is associated with a better prognosis in patients with localized/metastatic clear cell sarcoma? A population-based study. <i>Dr Tomohiro Fujiwara, Okayama University Hospital, Okayama, Japan</i>
08.55	114	Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. <i>Mr Jonathan Perera, RNOH, Stanmore, UK</i>
09.00		Questions

- 09.10 148 Evaluation of the effect of neoadjuvant chemotherapy on the resectability of extremity soft-tissue sarcoma. *Prof David Biau, Hôpital Cochin, Paris, France*
- 09.15 268 Soft tissue sarcomas in elderly patients: do we have to operate always? *Dr Michele Boffano, Orthopaedic Oncology AOU Citta' della Salute e della Scienza, Torino, Italy*
- 09.20 28 Vascular Proximity increase the risk of local recurrence in Soft-Tissue Sarcomas of the thigh - A retrospective MRI study. *Dr Andrea Sambri. IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy*
- 09.25 Questions
- 09.35 253 Free fillet flaps for reconstruction of massive oncologic resections. *Dr Lucas Kreutz Rodrigues, Mayo Clinic, Rochester, USA*
- 09.40 336 The orthoplastic approach in soft tissue tumors of the foot. *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy*
- 09.45 267 Wound healing complication after excision of soft tissue sarcomas: does it delay radiologic follow up and increase local recurrence rate? *Dr Michele Boffano, Orthopaedic Oncology AOU Citta' della Salute e della Scienza, Torino, Italy*
- 09.50 296 Unplanned excision of soft tissue sarcomas of the hand and the wrist. *Prof Vasileios Kontogeorgakos, First Department of Orthopedic Surgery, National and Kapodistrian University of Athens, Attikon University General Hospital, Athens, Greece*
- 09.55 43 Unplanned resections of soft tissue sarcomas – is further surgery necessary in every case? *Prof Hans Roland Dürr, Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 10.00 Questions

10.15 **REFRESHMENTS**

**KEYNOTE LECTURE**

- 10.45 Research in Rare Tumours - How to Collaborate  
*Prof Michiel Van de Sande, Professor of Orthopaedic Oncology, Leiden University Medical Centre, Leiden, Netherlands*

11.05 **CASE DISCUSSIONS**

**Chairs: Prof Michiel Van de Sande / TBC**

**PRESIDENTIAL LECTURE**

- 11.50 Progresses and future directions in musculoskeletal oncology and the role of International Societies  
*Prof Pietro Ruggieri, University of Padova, Italy*

12.30

## LUNCH

### IMPLANTCAST SYMPOSIUM

**Chairs / Moderators:** Mr. Rob Pollock, Royal National Orthopaedic Hospital, Stanmore, United Kingdom

**Prof. Pietro Ruggieri, University of Padova, Italy**

- 12.30 LUMiC® or 3D printed pelvic implants for sarcoma? *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, UK*
- 12.40 How the choice of surgical technique can influence clinical outcome in patients with 3D printed implants? *Prof. Daniel Kotrych, Szczecin, Poland*
- 12.50 Osteointegration of custom made implants, *Prof. Thomas Schubert, Brussels, Belgium*
- 13.00 Case reports: 1. Telangiectatic osteosarcoma of the pelvis 2. Secondary Chondrosarcoma in a Patient with Maffucci Syndrome. *Dr. Hazem Wafa, Head of Clinic, Orthopaedic Oncology and Knee Surgery, UZ, Leuven, Belgium*
- 13.10 Novel joint sparing implants, the London experience. *Mr Rob Pollock, Royal National Orthopaedic Hospital, Stanmore, UK*
- 13.20 Long term results of MUTARS® implants – analysis of 187 cases. *Dr. Elisa Pala, University of Padova, Italy*

## CHONDRAL TUMOURS

### KEYNOTE LECTURE

13.30

Controversies in Chondrosarcoma

*Prof Lee Jeys. Profesor of Orthopaedic Oncology, Royal Orthopaedic Hospital, Birmingham, UK*

### ENCHONDROMAS + ACT

**Chairs: Prof Davide Donati / Dr Jos Bramer**

- 13.45 242 The past, present and future in treatment of Atypical Cartilaginous Tumours. *Ms Claudia Deckers, Department of Orthopedics, Radboudumc, Nijmegen, Netherlands*
- 13.50 236 Outcome after intralesional curettage of highly-differentiated chondrosarcomas/atypical cartilaginous tumors (ACTs) of the extremities. *Prof Georg Omlor, University of Heidelberg, Department of Orthopaedic Surgery, Heidelberg, Germany*
- 13.55 343 Circulating tumour cells during surgery for chondral tumours. *Dr Rachel Baumber, Royal National Orthopaedic Hospital, London, United Kingdom*
- 14.00 316 Enchondroma and atypical cartilaginous tumor: To operate or not to operate. *Dr Berkay Doğan, Baltalimani Bone Diseases Training and Research Hospital, Istanbul, Turkey*
- 14.05 130 Review of 23 patients with low-grade chondrosarcoma who underwent surgical treatment, is intra-lesional curettage enough? *Dr Filipe Castelo, Centro Hospitalar Universitário do Porto, Porto, Portugal*



- 14.10 338 Limb lengthening for deformities in Ollier's disease: a systematic review in 121 patients (272 bone segments). *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*
- 14.15 Questions

## CHONDROSARCOMA

**Chairs: Prof Jay Wunder / Dr Luke Johnson**

- 14.30 150 Chondrosarcomas of the pelvis: about 106 operated cases. *Prof David Biau, Hôpital Cochin, Paris, France*
- 14.37 151 Excision of 87 primary malignant bone tumors of the pelvis. *Prof David Biau, Hôpital Cochin, Paris, France*
- 14.44 212 Outcome of surgical treatment of chondrosarcoma of the extremities and impact of surgical revision. *Prof Philipp Funovics, Department of Orthopedics and Trauma Surgery, Medical University of Vienna, Vienna, Austria*
- 14.51 46 Chondrosarcoma of the chest wall: A single-institution review of 50 cases. *Mrs Mina Laitinen, Helsinki University Hospital, Helsinki, Finland*
- 14.58 97 Extraosseous tumour component predicts disease specific survival better than the grade in conventional central chondrosarcoma of the proximal femur. *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 15.05 96 Dedifferentiated central chondrosarcoma. *Prof Lee Jeys, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 15.12 64 Impact of insurance status on chondrosarcoma diagnostic stage: implications for detection and outcomes. *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 15.19 Questions

## 15.30 REFRESHMENTS

## 16.00 EEC EWINGS SYMPOSIUM

**Ewing Sarcoma – current challenges in local treatment and future perspectives.**

**CHAIRS: Dr Dimosthenis Andreou - Division Chair Orthopedic Oncology at the Department of Orthopedics and Trauma, Medical University Graz, Austria. Prof. Dr. med. Beate Timmermann, Director of the Particle Therapy Clinic and Head of Medicine at the West German Proton Therapy Centre in Essen, Essen University Hospital, Germany**

**Upcoming international Ewing sarcoma trials - an update**

Inter-Ewing-1. *Dr JHM Merks, Princess Máxima Center for Pediatric Oncology, Netherlands*

iEuroEwing. *Professor Uta Dirksen, University Hospital Essen, Germany*

Discussion

**Interactive MDT – how would you locally treat these challenging cases?**

Discussion of 3-4 cases in an MDT format, short presentation of available evidence, followed by public voting

**CAMPANACCI LECTURE Introduced by Mr Rob Pollock / Mr Will Aston / Prof Rob Ashford / Ms Hel Havard**

17.30

The evolution of pelvic surgery. A journey from hind quarter amputation to custom reconstruction.

*Prof Paul Stalley, AM, Sydney***GALA DINNER****Tuesday 18th October****WHITTLE ROOM**

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome / Housekeeping****SPINE & SACRAL TUMOURS****Chairs: Mr Hanny Anwar / Mr Andy Johnson**

08.35	75	Epidemiology of surgically treated spinal tumors according to the German Society for Spine Surgery (DWG) registry. Dr Peter Knoell, <i>University Hospital Cologne, Cologne, Germany</i>
08.43	177	Surgical outcomes in patients operated for symptomatic metastatic spinal cord compression: A single institutional analysis to determine the change in quality of life and prognostic indicators for surgery. Dr Amrithlal Mascarenhas, <i>HCG Hospital, Bangalore, India</i>
08.51	339	Decompressive surgery for spine metastases: analysis of 49 patients from a single Institute. Prof Pietro Ruggieri, <i>Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy</i>
08.59	219	A preliminary Comparison of CT-guided Navigation-assisted Surgery versus conventional surgical Treatment of Osteoid Osteoma in the Spine. Dr Gerhard Hobusch, <i>Department of Orthopedic and Trauma Surgery, Medical University of Vienna, Vienna, Austria</i>
09.07		Questions
09.17	297	Surgical Treatment of Sacral Chordomas. A Retrospective Study of 26 cases. Dr Ioannis Trikoupis, <i>First Department of Orthopaedic Surgery, National and Kapodistrian University of Athens, Medical School, Attikon University General Hospital, Athens, Greece</i>
09.25	334	Modified surgical technique of sacrectomy in treatment of bone sarcoma and its impact on function and overall survival. Prof Daniel Kotrych, <i>ŞPomeranian Medical University, Szczecin, Poland</i>
09.33	142	Cryoablation of sacral Giant Cell Tumor using 3D printing: a case report. Dr Solomon Dadia. <i>Levin Center of Surgical Innovation &amp; 3D Printing, Tel Aviv, Israel</i>
09.41		Questions

09.51

## INTERACTIVE SPINE AND SACRAL TUMOUR SESSION WITH CASE DISCUSSIONS

10.15

## REFRESHMENTS

### TENO-SYNOVIAL GIANT CELL TUMOURS

**Chairs: Dr Gerard Powell / Prof Michiel Van de Sande**

- 10.45 162 Phototherapy in the Treatment of tenosynovial giant cell tumor. *Prof Frank Traub, Department of Orthopaedics and Traumatology, University Medical Center of the Johannes Gutenberg University,, Mainz, Germany*
- 10.50 238 Tenosynovial Giant Cell Tumour of the hip: Therapy, Results. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 10.55 258 One versus two-stage synovectomy of diffuse-type tenosynovial giant cell tumor (D-TGCT) of the knee: an international, retrospective, cohort study. *Mr Geert Spierenburg. Leiden University Medical Center, Leiden, Netherlands*
- 11.00 260 Active surveillance of diffuse-type tenosynovial giant cell tumors: a retrospective, multicenter cohort study. *Mr Geert Spierenburg. Leiden University Medical Center, Leiden, Netherlands*
- 11.05 283 Outcomes of tenosynovial giant cell tumour of the foot and ankle. *Mr James Barnett, Royal National Orthopaedic Hospital, Stanmore, United Kingdom*
- 11.10 Questions

### GCT OF BONE

**Chairs: Prof Domenico Campannacci / Prof Jendrick Hardes**

- 11.15 76 Intralesional curettage and bone graft for the treatment of bone GCT. Experience in a single institution since 1982. *Dr Ididre Gracia, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain*
- 11.20 106 Reduced dose intensity protocol of denosumab in treating advanced/unresectable giant cell tumour of the bone. *Dr Suraj Hindiskere, HCG Hospital, Bangalore, India*
- 11.25 168 Neoadjuvant denosumab in GCT: long term injection can decrease the risk of local recurrence. *Anastasia Tararykova, (N.N. Blokhin NMRCO), Moscow, Russian Federation*
- 11.30 181 Treatment of Giant Cell Tumor of Bone in the Distal Radius and Ulna. *Dr Michal Mahdal, First Department of Orthopedic Surgery, St. Anne's University Hospital, Brno, Czech Republic*
- 11.35 208 Secondary malignancy in giant cell tumor in the extremity: a single-center experience. *Dr Taemin Hong, Department of Orthopaedic Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*
- 11.40 342 Management and surveillance of metastatic giant cell tumour of bone. *Prof Christopher ML Gibbons, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom*
- 11.45 Questions
- 11.50 **Move to Fleming for Presidential Lecture**

12.30 **LUNCH**

**LONG TERM FUNCTIONAL OUTCOMES FOLLOWING DIAGNOSIS. JOINT SESSION WITH AHP**

**Chairs: Prof Sander Dijkstra / Dr Nicola Fabbri**

- 13.30 123 Providing insight in a patients' physical functioning in musculoskeletal oncology. *Ms Jorinde Denissen, Nijmegen, Netherlands*
- 13.38 140 Functional outcomes in patients undergoing resection and reconstruction surgery of proximal femur or pelvis bones after malignant bone tumor. A case series. *Dr Matilde Meneghini, Istituto Ortopedico Rizzoli, Bologna, Italy*
- 13.46 141 Intermuscular extremity myxoid liposarcoma can be managed by marginal resection following neoadjuvant radiotherapy. Mr Jonathan Perera, RNOH, Stanmore, UK
- 13.54 47 Long-term gait analysis after a rotationplasty, a cross-sectional follow-up study. *Ms Gitte Krebbekx, Amsterdam UMC (AMC), Amsterdam, Netherlands*
- 14.02 325 Stanmore Tumour Outcomes Project (STOMP): What is the patients' survivorship experience after extremity sarcomas? – A presentation of preliminary findings. *Ms Teja Joshi, Royal National Orthopaedic Hospital, London, United Kingdom*
- 14.10 Questions
- 14.20 272 Balance and Gait Outcomes after 1-year post-operative Hemipelvectomy Surgery? *Dr Sherron Furtado, RNOH, Stanmore, UK*
- 14.28 264 Life quality and functionality after internal hemipelvectomy. *Prof Burkhard Lehner, Orthopedic university clinic, Heidelberg, Germany*
- 14.36 9 Predictors of functional recovery among musculoskeletal oncology patients undergoing lower extremity endoprosthetic reconstruction. *Dr Aaron Gazendam, McMaster Hospital, Hamilton, Canada*
- 14.42 221 What are the survivorship issues that occur following proximal femoral replacement surgery for musculoskeletal cancer? A Systematic Review. *Dr Sherron Furtado. RNOH, Stanmore, UK*
- 14.52 Questions

**INVITED LECTURE**

- 15.02 Mental and Physical Wellbeing in Sarcoma - not just for patients  
*Dr Ahmed Aber. General Surgery Registrar/South London Rotation. H.Lecturer/Health Economics & Decision Science, University of Sheffield*

15.30 **REFRESHMENTS**

## OUTCOMES AND SCORING SYSTEMS

**Chairs: Mr Craig Gerrand / Dr Sherron Furtado**

- 16.00 95 Patient engagement in sarcoma research: benefits, challenges, importance, and implications. *Ms Caitlyn Ivany, McMaster University, Hamilton, Canada*
- 16.08 329 The Sarcoma-Specific Quality of Life Study (SARC-QoL): identifying key domains of health-related quality of life in adult patients with extremity soft tissue sarcoma. *Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA*
- 16.16 330 Patient-reported outcome measures to measure health-related quality of life in people with soft-tissue sarcoma: a systematic review of measurement properties of patient-reported outcomes. *Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA*
- 16.24 Questions
- 16.34 331 A systematic review of patient-reported outcomes used to measure health-related quality of life in soft-tissue sarcoma. *Dr Krista Goulding, Mayo Clinic Arizona, Phoenix, USA*
- 16.42 152 Establishing a sarcoma reference score for EQ-5D. *Mr Cédric Niggli, University Hospital Zurich, Zurich, Switzerland*
- 16.50 305 Meaningful interpretation of Toronto Extremity Salvage Score in people with soft-tissue sarcoma using Rasch analysis. *Dr Krista Goulding, McGill University Health Centre, Montreal, Canada*
- 16.58 256 Outcomes of Bone Sarcoma in the Over 90's. *Dr Laura Hartley, The Royal Orthopaedic Hospital NHS Foundation Trust, Birmingham, United Kingdom*
- 17.06 166 Comparative Survival Times for Patients Following Endoprosthetic Reconstruction After Primary and Metastatic Bone Tumour Resection Based on Disease Spread: A Retrospective Tertiary Centre Study. *Ms Jessica Harewood, Newcastle University, Faculty of Medical Sciences, Newcastle, United Kingdom*
- 17.12 Questions
- 17.22 **Close of Session**  
**Move to Fleming for Campannacci Lecture**

## Tuesday 18th October

### GIELGUD ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30		<b>Welcome / Housekeeping</b>
-------	--	-------------------------------

## RADIOLOGY

**Chairs: Dr Paul O'Donnell / Prof Thomas Schubert**

- 08.35 31 Prevalence and characteristics of benign cartilaginous tumours of the knee joint as identified on MRI scans. *Mr Johannes Nikolaus Woltsche, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*
- 08.40 87 How accurate is measurement on radiological images for resection and reconstruction in Orthopedic Oncology? *Dr Anto Gopurathingal, HCG Hospital, Bangalore, India*
- 08.45 225 A Deep Learning Model for Classification of Chondroid Tumors on CT-Images. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 08.50 197 Dual time point [18F]FDG PET/CT can differentiate benign from malignant musculoskeletal tumors. *Prof Thomas Schubert, Cliniques universitaires Saint-Luc, Department of Orthopaedic Surgery, Brussels, Belgium*
- 08.55 34 Artificial Intelligence Algorithm can predict the clinical course of Desmoid Tumors using Baseline MRI - A Feasibility study. *Dr Amir Sternheim, National Unit of Orthopaedic Oncology Tel-Aviv Medical Center, Tel-Aviv, Israel*
- 09.00 206 Is it safe to send patients with tumor endoprosthesis to MRI? Heating and displacement force testing of tumor endoprosthesis within the MR field. *Dr Marko Bergovec, Medical University Graz, Graz, Austria*
- 09.05 Questions
- 09.15 60 Diagnostic accuracy of the biopsy of soft tissue component of bone tumour with soft tissue extension. *Dr Idowu O.K, Oncology Unit, National Orthopedic Hospital Igbobi, Lagos, Nigeria.*
- 09.20 105 Preoperative imaging determines necessity of tissue biopsy in extraperitoneal lipomatous tumor. *Dr Chindanai Hongsaprabhas, Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*
- 09.25 99 Clinical and imaging features affecting the necessity of tissue biopsy in pathological long bone fractures. Department of Orthopaedics. *Dr Chindanai Hongsaprabhas, Department of Orthopaedics, Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand*
- 09.30 192 Does the histological presence of a nidus correlate with improved outcomes in osteoid osteoma treated with percutaneous radiofrequency ablation (RFA)? *Mr Amirul Adllan, Royal Orthopaedic Hospital, Birmingham, United Kingdom*
- 09.35 82 An Update Of Technical Tips Of Microwave Ablation and Ct-Guided Radiofrequency Ablation As A Part Of Minimally Invasive Techniques In Orthopedic Oncology - A Review Of 70 Cases From A Tertiary Care Center In India. *Dr Amar Kamat, HCG Hospital, Bangalore, India*
- 09.40 41 Incidental benign bone tumors on knee radiographs. *Dr Mustafa Karaca, Ankara University Medical Faculty, Ankara, Turkey*
- 09.45 Questions
- 09.55

**DEBATE 3: How do we do whole body staging for bone sarcomas? Moderator: Prof Thomas Schubert**

**Moderator: Prof Thomas Schubert**

Total Body PET is best. *Hattie Branford-White, Oxford Sarcoma Service*

MRI is better. *Paul O'Donnell, RNOH, Stanmore*

## 10.15 REFRESHMENTS

### MANAGING BLOOD LOSS IN ORTHOPAEDIC ONCOLOGY

**Chairs: Dr Rachel Baumber / Mr Andy Johnson**

- 10.45 48 Use of tranexamic acid to reduce post-operative bleeding in orthopaedic oncology. Dr Lorenzo Andreani, University of Pisa, Pisa, Italy
- 10.50 81 Prospective Evaluation of Tranexamic Acid in Metastatic Cancer Patients with Pathologic Fractures Treated with Total Hip Arthroplasty or Hemiarthroplasty. *Dr Caleb Yeung, Memorial Sloan Kettering Cancer Center, New York, USA*
- 10.55 298 The Safety and Efficacy of Tranexamic Acid in Oncology Patients Undergoing Endoprosthetic Reconstruction and a ROTEM-Based Evaluation of Their Hemostatic Profile: A Pilot Study. *Dr Ioannis Trikoupis, National and Kapodistrian University of Athens, Athens, Greece*
- 11.00 146 Reduction of blood loss by tranexamic acid in cases of lower extremity tumor resection and modular tumor endoprosthesis. *Prof Burkhard Lehner, Orthopedic university clinic, Heidelberg, Germany*
- 11.05 Questions
- 11.15 10 Tourniquet use in patients undergoing oncologic resection and endoprosthetic reconstruction of the knee. *Ms Patricia Schneider, McMaster University, Hamilton, Canada*
- 11.20 120 Use of regional anesthesia to reduce blood loss in isolated limb perfusion (ILP) - a pilot study. *Dr Maya Niethard, Department of Orthopedic Oncology, Helios Klinikum Berlin-Buch, Berlin, Germany*
- 11.25 344 Intra-operative TEG data to customize VTE risk and individualise care for sarcoma patients. *Dr Rachel Baumber, Royal National Orthopaedic Hospital, London, United Kingdom*
- 11.30 Questions
- 11.40 **Close**

## 12.30 LUNCH

### BASIC SCIENCE

**Chairs: Mr Kenneth Rankin / Dr Fabrice Fiorenza**

- 13.30 33 5-ALA-dependent fluorescence of musculoskeletal tumors in a chick chorio-allantoic membrane model. *Dr Wiebke Katharina Guder, Department of Orthopedic Oncology, University Hospital Essen, Essen, Germany*
- 13.36 39 In vivo massive bone allografts decellularized by a new perfusion process: preliminary results. *Dr Robin Evrard, Université Catholique de Louvain, Institut de recherche expérimentale et clinique, Chirurgie expérimentale et transplantation (CHEX), Brussels, Belgium*

- 13.42 254 Evaluation of candidate biomarkers for fluorescence-guided surgery in myxofibrosarcoma: An immunohistochemical and in-vitro evaluation study. *Mr Zeger Rijs, Leiden University Medical Center, Leiden, Netherlands*
- 13.48 231 Development of a Targeted Dual-Modality Radioimmunoconjugate for Image Guided Sarcoma Surgery. *Dr Corey Chan, Translational and Clinical Research Institute, Newcastle University, Newcastle upon Tyne, United Kingdom*
- 13.54 122 Feasibility of novel in-situ local tumor ablation and recycling machine using radiofrequency dielectric heating. *Dr Min Wook Joo, Department of Orthopaedic Surgery, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of*
- 14.00 Questions

## MISCELLANEOUS PAPERS

**Chairs: Dr Jakub Jagiello / Dr Michelle Ghert**

- 14.10 53 Clinical and functional results following partial or total claviclectomy without reconstruction for malignant clavicular tumours. *Dr Maria Anna Smolle, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*
- 14.16 243 Natural History, Risk Factors and Surgical Outcomes of Coxa Vara Deformity in Fibrous Dysplasia/McCune-Albright Syndrome. *Ms Maartje Meier, Leiden University Medical Center, Leiden, Netherlands*
- 14.22 285 Bioactive ceramics in the treatment of benign bone tumours and tumour-like lesions. *Prof Oleg Vyrva, Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine*
- 14.28 286 Aneurysmal bone cysts: a UK-wide tumour centre experience. *Mr Luckshman Bavan, Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom*
- 14.34 Questions
- 14.44 61 The oncology orthopedist Role – where do we fit? *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 14.50 62 Freezing in Florida – Are we ready for diversity? *Dr Ana Cecilia Belzarena, Miami Cancer Institute, Miami, USA*
- 14.56 273 Long term follow up in a High-Grade Sarcoma of the arm encasing the Radial Nerve treated by ISP technique. *Dr Sreeraj Rajan, Aster MIMS, Calicut, India*
- 15.02 274 Low-grade Myofibroblastic Sarcoma of femur: A case report. *Dr Sreeraj Rajan, Aster MIMS, Calicut, India*
- 15.08 90 Isolated limb perfusion and tumour endoprosthesis: a perfect combination for bone-associated sarcomas, or have we gone completely bonkers? *Dr Lars Erik Podleska, Department of Orthopaedic Oncology and Sarcoma Surgery, Essen University Hospital, Essen, Germany*
- 15.14 Questions
- 15.24 **Close of Session**

## 15.30 REFRESHMENTS





## PROGRAMME

(SUBJECT TO ALTERATION)

**Wednesday 19th October**

### FLEMING ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 [Welcome / Housekeeping](#)

#### PELVIC TUMOURS 1

**Chairs: Prof Daniel Kotrych / Mr Sam Patton**

08.35	111	Percutaneous Cementoplasty for the Pelvis in Bone Metastasis: 12-Year Experience. <i>Dr Jong Woong Park, National Cancer Center, Goyang, Korea, Republic of</i>
08.42	345	Minimally Invasive Fixation of Pelvic Metastases by CT-Assisted Surgical Navigation Improves Pain and Maintains Function at One Year. <i>Dr Nicola Fabbri, Memorial Sloan Kettering Cancer Center, New York, USA</i>
08.49	117	Outcomes of anterior minimally invasive (robotic & laproscopic) dissection of malignant bone tumours of the pelvis and sacrum: A multidisciplinary surgical approach. <i>Dr Pramod Chinder, HCG Hospital, Bangalore, India</i>
08.58	74	A 6-Point Protocol In Management Of Pelvic Bone And Soft Tissue Tumors. <i>Dr Amar Kamat, HCG HOSPITAL, BANGALORE, India Single Institute Outcome From India</i>
09.04	129	Complications of surgical management of bony tumors of the obturator framework. (Enneking Zone 3). <i>Speaker TBC</i>
09.10		Questions

- 09.20 284 New technique of allograft acetabulum reconstruction due to malignant bone tumours. *Prof Oleg Vyrva , Sytenko Institute of Spine and Joint Pathology, Kharkiv, Ukraine*
- 09.26 240 Mid to long-term clinical results of the LUMiC® prosthesis for reconstruction after periacetabular tumor resection. *Dr Richard Evenhuis, Leiden University Medical Center, Leiden, Netherlands*
- 09.32 182 Pelvic ring reconstruction with the non vascularized fibular free graft following internal hemipelvectomy. *Prof Toru Akiyama, Department of Orthopaedic Surgery, Saitama Medical Center, Jichi Medical University, Saitama, Japan*
- 09.38 164 Is Reconstruction Necessary Following Iliosacral Resection? A Comparison of Outcomes from Two Tertiary Sarcoma Centers. *Dr Jay Wunder / Mr Anthony Griffin, Division of Orthopaedic Surgery, Department of Surgery, University of Toronto Musculoskeletal Oncology Unit, Sinai Health System, Toronto, Canada*

09.44 Questions

#### 09.54 **PELVIC CASE DISCUSSION**

**Prof Daniel Kotrych / Mr Sam Patton**

#### 10.15 **REFRESHMENTS**

#### **PELVIC TUMOURS IN 3D**

**Chairs: Prof Paul Stalley AM / Mr Stephen Cannon**

- 10.45 116 Three-dimensional (3D) printed guides for malignant bone tumours: Institutional experience of 127cases and work-flow to design ideal guides for complex resections of pelvis and sacrum. *Dr Pramod Chinder , HCG Hospital, Bangalore, India*
- 10.53 169 Reconstructions surgery with custom-made 3D-printed pelvic prosthesis due to malignancy or benign bone tumors involving the acetabulum. Single-center retrospective cohort study with clinical follow-up including patients from 2014 to 2020. *Ms Müjgan Yilmaz, Rigshospitalet, Copenhagen, Denmark*
- 11.01 255 Clinical and biomechanical considerations to develop a custom made 3D printed pelvic reconstruction - a collaborative work between surgeons and engineers. *Dr Alba Gonzalez Alvarez, Universidad Carlos III de Madrid, Madrid, Spain*
- 11.09 323 Application of 3D printing in Guided Pelvic Resections: Experience from 2 Tertiary Referral Centers in the UK. *Mr M A Siddiqi, Nuffield Orthopaedic Center, Oxford, United Kingdom & RNOH, UK*
- 11.17 Questions
- 11.27 172 Does Patient Specific Instrumentation (PSI) improve local control when operating pelvic bone tumors : a controlled multicenter trial. *Prof Francois Guoin, Centre Léon Bérard, Lyon, France*

- 11.35 245 New Incentives and Pitfalls in Patient-Specific Pelvic Implants made by Additive Manufacturing. *Dr André Olivier, Vergelegen Mediclinic, Somerset West, South Africa*
- 11.43 217 High accuracy of positioning custom 3-dimensional printed pelvic implants in tumour and total hip revision surgery: a multicentre cohort study of 35 patients. *Dr Demien Broekhuis LUMC, Leiden, Netherlands*
- 11.51 337 The use of navigation vs custom-made saw jigs in computer assisted pelvic resection and reconstruction. What is better? *Prof Pietro Ruggieri, Department of Orthopedics and Orthopedic Oncology, University of Padova, Italy, Padova, Italy*
- 11.59 Questions

12.10

**DEBATE 4: To navigate or not in pelvic resections. Moderators: Prof Paul Stalley / Mr Stephen Cannon**

**Moderators: Prof Paul Stalley / Mr Stephen Cannon**

Navigation should be used for all internal hemipelvectomies. *Prof Lee Jeys, Royal Orthopaedic Hospital Birmingham, UK*

Navigation in pelvic surgery is not necessary. *Mr Will Aston, RNOH, Stanmore, UK*

12.30

**LUNCH**

**INVITED LECTURE**

13.30

Getting It Right First Time in Sarcoma. UK National GIRFT Project

*Prof Tim Briggs, CBE*

**COMPLICATIONS**

**Chairs: Prof Tim Briggs / Dr Jake Jagiello**

13.50

294

What is the complication rate in total femur replacement? Case series. *Dr Marisa Valentini, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria*

13.55

32

The effect of implant type on re-operation rates following endoprosthetic reconstruction surgery. *Ms Victoria Giglio, McMaster University, Hamilton, Canada*

14.00

247

Failures and management experience in proximal femur tumor endoprostheses. *Dr Osman Emre Aycan, Baltalimani Bone Disease Training and Education Hospital, Istanbul, Turkey*

14.05

269

Wound complications in Operations of the Thigh & Pelvis: Outcomes from the London Sarcoma Service's Bone and Soft tissue Sarcoma Team. *Ms Eliza Davison, Royal Free London NHS Foundation Trust, London, United Kingdom*

14.10

Questions

14.20

**EXTREME ORTHOPAEDIC SYMPOSIUM**

**Chair: Will Aston**

**Panel: Dr Jay Wunder / Prof Paul Stalley AM / Mr Andy Johnston / Prof Danyl Kotrych / Dr Jos Bramer / Prof Lee Jeys**

Invited complex case discussions

15.10 EMSOS Closing Ceremony and Prize Giving

16.00 End of Meeting

## Wednesday 19th October

### WHITTLE ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 Welcome / Housekeeping

#### ADVANCES IN DIAGNOSIS, STAGING AND SURVEILLANCE OF SARCOMAS

Chairs: Prof Andreas Leithner / Prof Ramses Forsyth

08.35 23 Liquid biopsy for monitoring paediatric Ewing sarcoma patients. *Prof Andreas Leithner, Department of Orthopedics and Trauma, Medical University of Graz, Graz, Austria*

08.40 86 A Review of 1884 Core Biopsies In Orthopedic Oncology - A Single Institute Experience. *Dr Anto Gopurathingal, HCG hospital, Bangalore, India*

08.45 244 Sensitivity, specificity and predictive values of tru-cut biopsy in primary localized myxoid liposarcoma of the extremities. *Dr Gianmarco Tuzzato, Unit of 3rd Orthopaedic and Traumatologic Clinic Prevalently Oncologic, IRCCS Istituto Ortopedico Rizzoli, Bologna, Italy*

08.50 173 Study of the spatial heterogeneity of the microenvironment of osteosarcoma by innovative histopathological and mechano-biological approaches: role in resistance to treatment. *Prof Anne Gomez-Brouchet, Institut Universitaire du Cancer de Toulouse, Toulouse, France*

08.55 100 Soft tissue solitary fibrous tumor: is histopathological pattern sufficient for defining prognosis or do we need further biomolecular insights and markers? *Dr Guido Scoccianti, Careggi University Hospital - Department of Orthopaedic Oncology, Firenze, Italy*

09.00 Questions

09.10 312 Surface Osteosarcomas. A Reclassification of the Lesions. *Dr habib nouri, private hospital, tunis, Tunisia,*

09.15 110 2b or not 2b :The periosteum is the question. *Prof Lee Jeys,Royal Orthopaedic Hospital, Birmingham, United Kingdom*

09.20 271 Myxoid liposarcoma 10-year surveillance programme. *Mr Ethan Caruana, Manchester University NHS Foundation Trust, Manchester, United Kingdom*

09.25 56 The Surveillance After Extremity Tumor Surgery (SAFETY) International Randomized Controlled Trial. *Dr Michelle Ghert, McMaster Hospital, Hamilton, Canada*

09.30 222 Non-invasive detection of soft tissue sarcoma using volatile organic compounds in exhaled breath: a pilot study. *Prof Michiel Van de Sande, Leiden University Medical Center, Leiden, Netherlands*

09.35 Questions

### INVITED LECTURE

09.45 Medico-legal aspects of sarcomas  
*Prof Rob Grimer, Royal Orthopaedic Hospital, Birmingham, UK*

### 10.15 REFRESHMENTS

### INNOVATION AND FUTURE PERSPECTIVES

**Chairs: Prof Philipp Funovics / Mr Kenneth Rankin**

10.45 103 Primitive Study on a 3D Preoperative Planning System for Bone and Soft Tissue Tumors Using a Virtual Reality Game Console. *Dr Munenori Watanuki, JR Sendai Hospital, Sendai, Japan*

10.52 299 Automated 3D reconstruction and biomechanical adjustment on virtual 3D models for complex hip joint reconstruction pre-surgery planning. *Mr Simonas Utkus, Republican Vilnius University Hospital, Vilnius, Lithuania*

10.59 289 3D-printing and computer navigation in preoperative planning and surgical management of soft tissue sarcoma. *Dr Juan P. Zumarraga, Hospital Metropolitano, Quito, Ecuador*

11.06 291 3D virtual reality simulation for musculoskeletal tumors: reconstruction and simulated surgery. A preliminary 15 case study. *Dr Juan P Zumarraga, Universidad San Francisco de Quito, Quito, Ecuador*

11.13 115 Planning and executing surgery using 3D printing technology - with 3D designing, modeling and rapid prototyping; end-to-end tips from an Engineer's perspective in an orthopedic oncology team. *Mr Kumar Sukrit, The Yellow Ribbon (Manfrini & PHO Institute of Sarcoma Research), Bangalore, India*

11.20 Questions

11.30 189 Using augmented reality for intraoperative guidance during needles placement for cryoablation of Desmoid tumors. *Dr Eran Golden, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel*

11.37 161 Phototherapy in the Treatment of Malignant Bone Tumors. *Prof Frank Traub, Department of Orthopedic and Traumatology, University Medical Center, Mainz, Germany*

11.44 278 SARCOSIGHT: A Randomised-Control Trial of Fluorescence Guided Sarcoma Surgery Versus the Standard of Care. *Dr Marcus Brookes, The Newcastle upon Tyne Hospitals NHS Foundation Trust, Newcastle upon Tyne, United Kingdom*

- 11.51 250 Indications and clinical outcomes of oncological patients treated with carbon-fibre plates: an international multi-institutional study. *Mr Zeger Rijs, Leiden University Medical Center, Leiden, Netherlands*
- 11.58 Questions
- 12.10 Close of session

12.30 **LUNCH**

**INTERACTIVE EPR INFECTION SYMPOSIUM**

**Chairs: Mr Tariq Azamgarhi / Dr Michelle Ghert**

- Pre-workshop poll – to establish current practice
- 13.30 98 Patient and Surgical Risk Factors for Surgical Site Infection in Lower Extremity Oncologic Endoprosthetic Reconstruction: A Secondary Analysis of the PARITY Trial Data. *Dr David Slawaska-Eng, McMaster University, Hamilton, Canada*
- 13.37 91 Risk factors for all-cause early re-operations in patients undergoing tumor resection and endoprosthetic reconstruction: a secondary analysis from the PARITY trial. *Dr Joseph Kendal, University of California, Los Angeles, Santa Monica, USA.*
- 13.44 232 Silver coated tumour prostheses in oncologic indications : about 56 cases with 53 months follow up. *Dr Fabrice Fiorenza, Department of orthopaedic surgery-Dupuytren Teaching Hospital, Limoges, France*
- 13.51 27 Silver-coated megaprotheses (PorAg®) can be protective against reinfection in the treatment of oncologic prosthesis infection. *Dr Andrea Sambri. IRCCS Azienda Ospedaliera Universitaria di Bologna, Bologna, Italy*
- 13.58 239 The infected megaprosthesis: treatment strategies, results. *Dr Alexander Klein, Orthopaedic Oncology; Department of Orthopaedics and Trauma Surgery, Musculoskeletal University Center Munich (MUM), University Hospital, LMU Munich, Munich, Germany*
- 14.05 Discussion

**INVITED LECTURE**

- 14.10 The Parity Trial and Beyond *Dr Michelle Ghert.*
- 14.25 Pre-symposium survey results of current practice
- 14.30 Where do we go from here? An Infectious Diseases Perspective. *Dr Simon Warren, RNOH Stanmore, UK*
- 14.40 Does current practice provide adequate intra-operative cover? A Pharmacist's perspective. *Tariq Azamgarhi, RNOH Stanmore, UK*
- 14.45 Discussion
- 15.05 Live poll - What are the next steps for antibiotic prophylaxis?
- 15.10 **Close of Session**

## Wednesday 19th October

### GIELGUD ROOM

Session Time	Abstract Number	Session Topic & Presenter
--------------	-----------------	---------------------------

08.30 **Welcome / Housekeeping**

#### METASTATIC BONE DISEASE 1

**Chairs: Prof Thomas Baad-Hansen / Prof Davide Donati**

08.35	93	A patient-specific fracture risk assessment tool for femoral bone metastases; using the BOne Strength (BOS) score in clinical practice. <i>Dr Florieke Eggermont, Orthopaedic Research Lab, Radboud university medical center, Nijmegen, Netherlands</i>
08.40	207	Predicting proximal femoral pathologic fractures from digitally reconstructed radiographs using deep learning in advanced cancer patients. <i>Dr Yong-Suk Lee, Department of Orthopaedic Surgery, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Seoul, Korea, Republic of</i>
08.45	57	External validation of the 2013-SPRING model for survival prediction in surgically treated patients with metastases to the appendicular skeleton. <i>Dr Maria Anna Smolle, Department of Orthopaedics and Trauma, Medical University of Graz, Graz, Austria</i>
08.50	72	Development of a scoring system for survival following surgery in metastatic bone disease. <i>Dr Rachel Baumber, Royal National Orthopaedic Hospital, London, United Kingdom</i>
09.55	5	Clinical Outcome Differences in the Treatment of Impending Versus Completed Pathological Long-Bone Fractures. <i>Dr Olivier Groot, Massachusetts General Hospital, Boston, USA</i>
08.55	7	The preoperative machine learning algorithm for extremity metastatic disease can predict 90-day and 1-year survival: two international external validations. <i>Dr Olivier Groot, Massachusetts General Hospital, Boston, USA</i>
09.00		Questions
09.10	165	Trends in surgical treatment of long bones diaphysis metastases among orthopedic surgeons. <i>Mr Dawid Ciechanowicz, Department of Paediatric Orthopaedics and Oncology, Pomeranian Medical University, Szczecin, Poland</i>
09.15	65	Patient survival after resection of skeletal metastases and endoprosthetic reconstruction: A nation-wide cohort study with a single decision-making oncological institution. <i>Prof Blaž Mavčič, University Medical Centre Ljubljana, Department of Orthopaedic Surgery, Ljubljana, Slovenia</i>
09.20	248	Survival and surgical outcomes in patients with tibial metastases: a dual-center study. <i>Dr Tommaso Greco, Department of Orthopaedics and Trauma Surgery, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy</i>

- 09.25 85 Outcomes of Intercalary Endoprostheses as a Treatment for Metastases in the Diaphysis of Femur and Humerus. *Dr Michal Mahdal, First Department of Orthopedic Surgery, St. Anne's University Hospital, Brno, Czech Republic*
- 09.30 12 Sustained inflammation and deranged cytokine expression impair healing of pathological fractures in the presence of breast cancer cells. *Prof Francis Lee, Yale, New Haven, USA*
- 09.35 6 Body composition predictors of mortality in patients undergoing surgery for long bone metastases. *Dr Olivier Groot, Massachusetts General Hospital, Boston, USA*
- 09.40 Questions

#### INVITED LECTURE

- 09.50 11 A minimally invasive 4-dimensional AORIF procedure for periacetabular osteolytic metastases in a prospective cohort of 55 patients. *Prof Francis Lee, Yale, New Haven, USA*

#### 10.05 REFRESHMENTS

#### METASTATIC BONE DISEASE 2

**Chairs: Prof Robert Ashford / Dr Michele Boffano**

- 10.45 92 Cancer ablation and focal fixation for focal osteolytic metastatic lesions in the proximal or distal femur: One long-implant fits all? or Personalized focal AORIF oncologic fixation? *Prof Francis Lee, Yale University, New Haven, USA*
- 10.50 80 Comparison of Carbon Fiber and Titanium Intramedullary Nails In Orthopaedic Oncology. *Dr Caleb Yeung, Massachusetts General Hospital, Boston, USA*
- 10.55 147 Do cemented standard-length femoral stems have enough longevity for the pathological fractures of the femoral neck with metastatic lesions? A retrospective study. *Dr Pakjai Tuntarattanapong, Department of Orthopedics, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand*
- 11.00 179 Megaprosthesis for Metastatic Bone Disease- A Comparative Analysis. *Dr Joachim Thorkildsen, Oslo Univeristy Hospital, Oslo, Norway*
- 11.05 306 Options and Challenges when treating Bone Metastatic Renal Cell Carcinoma. *Dr Mihnea Ioan Gabriel Popa, University Emergency Hospital, Bucharest, Romania*
- 11.10 228 Surgical management options for long-bone metastasis. *Dr Bogdan Stefan Cretu. "Carol Davila" University of Medicine and Pharmacy, Bucharest, Romania*
- 11.15 346 Hybrid Reconstruction with Modular Cemented Intercalary Prosthesis and Plating for Metastatic Disease of the Humerus Provides Durable Fixation and Excellent Functional Outcome. *Dr Nicola Fabbri, Memorial Sloan Kettering Cancer Center, New York, USA*
- 11.20 Questions



## KEYNOTE PRESENTATION

- 11.30 The Metastatic BOAST and other BOOS Successes.  
*Prof Rob Ashford, Professor of Orthopaedic Oncology, University of Leicester*  
President British Orthopaedic Oncology Society (BOOS)

## 11.45 BOOS AGM

**Chairs: Prof Rob Ashford, President & Ms Gill Cribb, Hon Sec**

## 12.30 LUNCH

## BOOS INTERACTIVE SESSION

- 13.30 NATIONAL EPR DATABASE. Professor Rob Ashford, Professor of Orthopaedic Oncology, University of Leicester, President British Orthopae
- 13.40 BOOS DIPLOMA- HOW DID IT GO?. Miss Hattie Branford-White, Oxford Sarcoma Service
- 13.50 UK SARCOMA FELLOWSHIPS- TRAINING THE NEXT GENERATION. Jonathan Macdonald, Royal Orthopaedic Hospital, Birmingham
- 14.00 CAN WE AGREE WHICH DATASETS to COLLECT FOR PRIMARY BONE SARCOMA? Craig Gerrand, London Sarcoma Service
- 14.10 COLLABORATIVE RESEARCH- HOW AND WHO? Mr Kenny Rankin, Newcastle
- 14.20 [Close of Session](#)

## Wednesday 19th October

### OLIVIER ROOM 2nd Floor

- 12.30 **LUNCH - Euro Ewings Consortium**  
Local Therapy Networking Lunch (**Closed Meeting - EEC members only**)
- 14.30 **Close of Session**